The last exon of the CJ-INH gene was screened for point mutations in 36 unrelated hereditary angioedema patients. Mutations were found in eight patients, predicting changes in the short COOH-terminal region which anchors the reactive site loop on its COOH-terminal side. The effects of each of these mutations were examined in transiently transfected Cos-7 cells. Complete intracellular retention or degradation was observed with substitutions in the COOH-terminal strands 4B or 5B: Leu459Pro, Leu459-+Arg, and Pro467-Arg were all blocked at early stages of intracellular transport, but differences in the immunofluorescence patterns indicated that a significant fraction of the Leu459Pro and of the Pro467-Arg proteins reached a compartment distinct from the endoplasmic reticulum. In line with previous findings with al-antitrypsin, chain termination within strand 5B resulted in rapid degradation. Mutant Val451-+-Met, in strand 1C, and mutant Pro476-+Ser, replacing the invariant proline near the COOH terminus, yielded reduced secretion, but these extracellular proteins were unable to bind the target protease Cls. Presence of low levels of both dysfunctional proteins in patient plasmas defies the conventional classification of C1 inhibitor deficiencies as type I or type II. These data point to a key role of certain residues in the conserved COOH-terminal region of serpins in determining the protein foldings compatible with transport and proper exposure of the reactive site loop. (J. Clin. Invest. 1995. 95:350-359.)
Introduction C1 inhibitor (Cl inh),' a highly glycosylated plasma protein is a member of the serpin family of protease inhibitors (1) (2) (3) P1 residue, i.e., the reactive center residue of the serpins, which is exposed on a loop (4, 5) , is recognized by the substrate binding site of the target protease. Proteolytic attack on the peptidyl bond carboxy-terminal to the P1 residue ensures the formation of a very stable complex between the inhibitor and the target protease. C1 inh is the only inhibitor of the CIr and Cls subcomponents (6) of the first component of complement and therefore plays a key role in the control of the classical pathway of complement activation. It also plays a major role as an inhibitor of kallikrein and coagulation factor XIIa (for a review see reference 7) .
Defects in the CJ-INH gene (8) result in hereditary angioedema (HAE), a disease transmitted as an autosomal dominant trait and characterized by episodic acute subcutaneous or mucosal swellings (7). According to the plasma level of C1 inh two distinct forms of HAE were defined (9) . The more common type I is characterized by low plasma levels of the protein (5-30% of the normals) and the less frequent type II by normal or elevated levels of dysfunctional protein.
The CJ-INH gene consists of 8 exons distributed over a DNA stretch of 17 kb and contains 17 repetitive elements of the Alu family within its introns (10) . Most patients diagnosed as type II have single amino acid substitutions at (11) (12) (13) (14) or near (15) (16) (17) the reactive center residue, although changes off the reactive center have also been reported to result in a dysfunctional Cl inh protein (18) . Many different molecular defects determine type I HAE. Alu-mediated gene rearrangements (partial deletions or duplications) have been found in 15-20% of type I HAE families (19). The majority of HAE patients appears to carry point mutations or small deletions or insertions which may be located anywhere within CJ-INH gene.
Exon 8, which encodes the reactive site of the C1 inh protein, was examined in patients who had failed to reveal major structural gene rearrangements (19) . Here, we describe the detection of eight point mutations clustered downstream of the reactive site in the COOH-terminal region of the C1 inh protein and characterize their phenotypes.
Methods
Subjects. We studied 36 unrelated type I HAE patients without gene alteration detectable by DNA blot analysis. Among these patients, seven had no familial history of the disease.
Amplification ofgenomic DNA by PCR. Exon 8 was amplified using oligonucleotide primers El (5' GTGAACITGAACTAGAGAAAGC 3') and E2 (5' TGAGGATCCCACGAACTGCCAG 3') as shown in respectively (10) . 1 pg of genomic DNA isolated from peripheral white blood cells was used for amplification by PCR in a 100 y1 reaction with two units of Taq polymerase (AmpliTaq; Perkin Elmer, Norwalk, CT). The reaction was carried out in a Techne PHC1 or PHC2 thermocycler for 25 or 35 cycles with an annealing temperature of 60°C. Schematic presentation of the region encompassing the coding portion of exon 8 , that was amplified enzymatically from the patient genomic DNA. (B) the schematic diagrams depict the heteroduplex molecules formed between the amplified patient DNA and the end-labeled antisense (left) or sense (right) wild-type probe. The HgiAI polymorphism (G or A at codon 458, see Fig. 2 ), was detected with the antisense probe upon hydroxylamine treatment. An example of mutation detection is provided by the P467R mutation, revealed in the hydroxylamine reaction (HA) by the reactivity of a mismatched C at codon 467 in the sense probe (see Fig. 2 ). The adjacent T of the sense probe was also reactive with osmium tetroxide (01).
Chemical cleavage of mismatches. The probes and heteroduplexes between radiolabeled wild-type DNA and unlabeled patient DNA were produced as described by Grompe et al. (20) . Modification of mismatched cytosine and thymine with hydroxylamine and osmium tetroxide, respectively, were carried out as described by Cotton et al. (21) with minor modifications: the heteroduplexes were incubated at 370C for 1 to 3 h in a freshly prepared 2.5 M hydroxylamine hydrochloride (Merck, Darmstadt, Germany) solution titrated to pH 6 with diethylamine (Fluka AG, Buchs, Switzerland) or at 370C for 1 h in 5 mM Hepes, pH 8.0/0.5 mM EDTA/0.035% osmium tetroxide (Aldrich, Chemical Co., Ltd., Milwaukee, WI)/3% pyridine (Aldrich Chemical Co., Ltd.). The incubation time in piperidine (Merck) was reduced to 20 min. Samples were electrophoresed in 5% denaturing polyacrylamide gels.
Direct sequencing ofPCR amplified DNA. The double stranded DNA product was gel purified and 0.2 pmoles were subjected to 25-35 cycles of asymmetric amplification with 25 pmoles of a single primer in a 50-Il reaction volume. Single strand DNA was precipitated in 2 M ammonium acetate with one volume of ethanol and the dried DNA pellet was resuspended in 5 Il H20 and sequenced using the dideoxy chain termination method (Sequenase 2.0; US Biochemical Corp., Cleveland, OH).
Cl inh expression plasmids. A cDNA expression plasmid containing the complete coding sequence of a wild-type Cl inh was constructed using the pSVL vector (Pharmacia LKB Biotechnology Inc., Piscataway, NJ). This construct was similar to a previously described expression plasmid (22) , except that the full-length cDNA (2) was transferred from a pBluescript KS+ (Stratagene, La Jolla, CA) intermediate vector into pSVL by using the unique XhoI and XbaI sites. The PCR amplified exon 8 fragments (see Fig. 1 A) were cleaved at the EcoRI site at the intron 7/exon 8 boundary (10) and used to replace the corresponding fragment of the wild-type expression plasmid, from the unique EcoRI site of the cDNA to the unique SmaI site of pSVL. The EcoRI site present in the pSVL vector had been destroyed by partial digestion and religation after filling-in the 5' overhangs. Clones corresponding to mutant alleles were selected using enzymes which recognized either the mutation directly or the associated allelomorphism at the HgiAI site in exon 8, which was known from previous pBluescript KS+ plasmid subcloning. The entire coding portion exchanged was sequenced according to the Sequenase protocol (U. S. Biochemical Corp.). Clones differing only for the biallelic HgiAI polymorphism at codon 458 were used as controls and did not differ in their pattern of expression. In the case of a patient with a double point mutation (family F40), the mismatch primer method (23) was used to introduce separately each mutation in the PCR amplified exon 8 fragment. The primers containing the mutations (underlined) of this patient were on the coding strand E4 (5' TCTTTGAAGTGGAGCAGCCCT 3') and E6 (5' TTCCTCTTCGTGC-GCTGGGA 3').
Transient expression in COS-7 cells, metabolic labeling, and immunoprecipitation. Cos-7 cells were seeded at 3. I0 per 25 cm2 flask in DME plus 10% fetal calf serum one day before transfection with 5 /g of DNA using DEAE dextran (24) . The calcium phosphate mediated transfection method was also used in some experiments with the following modifications (25) : the precipitates were formed on ice for 90 min and cells were exposed to precipitates for 14-16 h in 100 ,uM chloroquine (Sigma Chemical Co., St 21) . In addition to the cleavage product expected from the G to A transition which is responsible for the known HgiAI allelomorphism (2), mismatches were detected in eight patients (see the example in Fig. 1 B) . In one of these (not shown), the CCM pattern indicated the presence of two sites of mutation distinct from the G/A allelomorphism. No additional mutation was found in this region when all 36 unrelated patients were re-examined by using the recent FAMA (Fluorescence Assisted Mismatch Analysis) methodology (29) , although this more powerful method revealed patient-specific mutations, located in other exons, in 33 patients of this group (data not shown).
To identify the mutations, sequencing was performed, directly on the PCR products, in the regions where the mismatches had been localized. Eight patient-specific nucleotide substitutions were identified ( Fig. 2) , of which the C to T transition, responsible for the R472stop change, was found in two unrelated patients and the two which are connected with a dotted line in Fig. 2 were found in the same patient, confirming the complex CCM pattern alluded to above. This patient carries a C to G transversion that changes the glutamine 452 to a glutamic acid and a T to G transversion that produces a leucine to arginine substitution at position 459. This latter mutation destroys the recognition site for the enzyme HgiAI (GTGCTC underlined in Fig. 2 ) which is polymorphic in the normal population (2) . In another patient a mutation was found, again at the fifth position of the HgiAI restriction site. In this case, the T to C transition produces a leucine to proline substitution. The other mutations identified are shown in Fig. 2 . It is striking that all the mutations were found located downstream of the reactive site argine 444, marked with an asterisk in Fig. 2 .
To reconstruct the patient haplotypes, a 434-bp-long segment obtained by Bglm digestion of the PCR amplified exon 8 Figure 2 . Coding sequence of exon 8 and mutations identified in type I hereditary angioedema patients. Nucleotide changes and the predicted amino acid substitutions are shown with boldfaced letters. Numbers above the triplets refer to codons of the Cl inh protein (10) . A double point mutation is marked with arrowheads connected by a dotted line. An HgiAI restriction site, which is polymorphic in the population due to the presence of a G or an A at the V/M codon 458 (2) , is underlined. The reactive center arginine is marked by an asterisk. Each of the mutations shown was family-specific except the R472stop, which was found in two apparently unrelated families.
sequence was cloned into the plasmid pBluescript KS+ (Stratagene). These clones allowed us to establish by sequence analysis that, in the case of the patient with the double point mutation, both changes were on the same chromosome. It was also noted that all mutations in exon 8 were associated with a G at the first position of the polymorphic HgiAI site (HgiAI+ alleles). All patients appeared to be heterozygous for the HgiAI site except the two unrelated patients with the R472stop mutation. The latter, however, generates a new HphI site. These observations facilitated the selection of the corresponding constructs for expression studies. Clones with the double point mutation were identified because the mutation at codon 459 destroys the HgiAI site. Similarly, the L459P mutant clones were also HgiAL-. Thus, the two patients with mutations in this codon were not HgiAI heterozygotes, according to the HgiAI polymorphism. The other constructs were selected either by HphI digestion for the R472 stop mutation or by virtue of the association of the mutation with the HgiAI+ alleles. The entire portion exchanged around exon 8 was sequenced in each of the expression plasmids selected.
Effects of the mutations on intracellular transport and stability of the protein. To characterize the functional correlates of each mutation, transient expression studies were carried out in Cos-7 cells. In the case of the double point mutation (see Fig. 2 ) the consequences of each change were tested separately. Fig. 3 shows that mutations in the carboxyl end of the Cl inh protein affect protein stability and/or secretion. Compared with wild-type Cl inh, the V451M and P476S mutant proteins were only partially secreted, while only trace amounts were detected in the extracellular medium for the F455S mutant and no protein was found secreted significantly above the Cos-7 background for the R472stop, L459P, P467R, and Q452E+L459R mutants. In the latter case, expression testing of each mutation separately showed that the L459R mutation was responsible for the effect observed when both mutations were expressed together. The Q452E protein seemed to behave as wild-type Cl inh, in that it was efficiently secreted. Fig. 4 shows pulse-chase experiments in which Cos-7 cells transfected with wild-type, R472stop, V451M, and P476S expression plasmids were labeled for 15 min and chased up to 8 h. The major band observed in the intracellular lysates corresponds to a partially glycosylated protein. The fully glycosylated Cl inh cannot be detected in the intracellular lysates of wild-type transfected cells, indicating that it is rapidly exported to the extracellular medium. After a 4 h chase, nearly all labeled wild-type Cl inh is secreted. The R472stop protein, which is not secreted, is degraded intracellularly whereas the intracellular forms of the partially secreted V45 IM and P476S proteins are more stable. The latter two proteins begin to appear significantly in the extracellular medium after a 1 h chase period, like wildtype Cl inh. In this pulse-chase experiment and in other experiments with CI inh mutants, the defective proteins accumulating within the cell were always found to be partially glycosylated. To examine if they accumulate at an early step of intracellular shown in Fig. 2 are summarized in the line "Secretion." In the case of the double mutant (changes connected with a dotted line) the phenotype is indicated below the L459R change, which is responsible for the lack of secretion (see Fig. 3 ). Three types of immunofluorescence staining were observed: type I is wild-type like, type 2 is essentially confined to the ER, and type 3 is intermediate (see Fig. 7 and text) .
transport, mutant proteins and wild-type CI inh were treated with endoglycosidase H after a 5-h labeling period (Fig. 5) . All mutant proteins were found to be sensitive to endo H, whereas low but significant amounts of endo H resistant, highly glycosylated protein were found in the lysates of cells producing wildtype Cl inh. Upon longer exposures (not shown), endo H resistant forms of Cl inh were detected only in the lysates of cells producing wild type Cl inh and in those of cells producing the V45 lM and the P476S mutant proteins, which are partially secreted. The latter mutant proteins and wild-type Cl inh are detected only at low levels after conversion to endo H resistance, because subsequent maturation steps leading to complete glycosylation and secretion are relatively fast. This interpretation is consistent with the results of pulse-chase experiments like the one shown in Fig. 4 , in which longer exposures (not shown) revealed only a faint, continuous distribution of highly glycosylated wild-type intracellular C1 inh. Given that wildtype C1 inh produced in transfected Cos cells is efficiently secreted after tunicamycin treatment (22) it is unlikely that mutant proteins are blocked in their intracellular transport for lack of proper glycosylation. More likely, the endo H sensitivity suggests that they never reach the medial Golgi where conversion to endo H resistance occurs (30) . The Fig. 6 ) was sometimes observed with mutant P467R, although it gave, in the great majority of transfected cells, a type 3 pattern. Moreover, a fraction of F455S transfected cells, which secrete traces of Cl inh, had a pattern closer to the type 1 staining.
The partially secreted mutant proteins V451M and P476S are dysfunctional. The ability of the partially secreted V45 IM and P476S mutant Cl inh protein to bind the target protease Cls was investigated. In addition, mutant F455S, which is secreted only in trace amounts, and mutant Q452E, which is normally secreted, were also tested for functional activity. Fig. 8 demonstrates that the V451M, P476S, and F455S mutant proteins have remarkably reduced capacity to bind CIs and do not behave as substrates. A very faint band at the position of the C I inh/C Is complex was seen upon long exposures but, relative to the amount of Cl inh present in the assay, only the F455S mutant, which is secreted in trace amounts, may have some residual capacity to bind Cls. In all cases, the amount of complexes was the same when the extracellular medium was incubated with 1 or 5 ug of CIs, ruling out the possibility that the trace reactivities of these mutant C1 inhibitors with CIs are due to selective recognition of a minor fraction of C Is which would have an adequate conformation for these mutants. Thus, the secreted fractions of both mutant proteins V451M and P476S are dysfunctional. Moreover, like the recently described PlO mutant C1 inhibitor Mo (34), they do not behave as substrates. Fig. 8 also shows that the secretion-competent Q452E mutation (Fig. 3) , found in association with the pathogenic L459R mutation, also has no effect on the capacity of Cl inh to bind CIs.
Cl inhibitor antigenic levels in the plasmas of patients from families FIO and F30, who carry the V451M and the P476S mutation, respectively, were determined by RIA with mAbRH as described (28, 33) and were found to be in the 25-30% range of normals. Their functional C1 inh levels, determined by RIA using Sepharose 4B-bound Cls (28) were moderately but consistently lower than the antigenic Cl inh levels (data not shown). Since no significant increase of cleaved Cl inh or of Cls-Cl inh, kallikrein-Cl inh or Factor XII-Cl inh complexes was found (not shown) these data suggested the presence of low levels of dysfunctional Cl inh in their plasmas. Furthermore, the analogy with the nonsubstrate-like behavior of the PlO mutant Cl inhibitor Mo (34) prompted us to examine the recombinant proteins V451M and P476S and the plasmas of patients carrying these mutations by using the monoclonal antibody KOK12, which is specific for cleaved or complexed normal Cl inh and recognizes the uncleaved mutant Cl inhibitor Mo (34) . These studies demonstrated that the recombinant V451M and P476S proteins are in a conformation which is recognized by KOK12 (34a) and confirmed the presence, in plasmas from patients carrying these mutations, of significant levels of altered Cl inh which is recognized by this conformation-specific monoclonal antibody (34b).
Discussion
Recent genetic studies of HAE underscore the heterogeneity of this disease, at the molecular level. Screening of HAE patients for mutations in the CJ-INH gene should provide to families the possibility of early DNA diagnosis. Moreover, in patients without family history (at least 7 out of 36 unrelated patients in the group described here), mutation screening of all exons of the CJ-INH gene is a rapid and efficient way to prove the genetic nature of the disease. Mutations resulting in amino acid substitutions, even if patient-specific, often require additional investigations in order to demonstrate that they are responsible for the disease. Thus, mutation screening and transfection studies to determine the biochemical consequences of the predicted amino acid substitutions were applied initially to exon 8, which codes for a relatively large carboxy-terminal portion of the Cl inh protein, including the reactive site loop.
While the number of unrelated patients with a mutation in exon 8 (8/36) is roughly proportional to the fraction of Cl-INH coding sequence screened (84 out of 478 amino acids are encoded in exon 8) the distribution of these mutations is highly unbalanced. All were found clustered downstream of the reactive site residue R444. However, several single nucleotide substitutions affecting the reactive site residue R444 itself (11) (12) (13) (14) , or upstream residues within /6 strand 4A (15) (16) (17) 35) , have been described in type II patients. In these cases the mutations affected the reactive site loop, leading to production of a secreted but dysfunctional protein. Apparently, amino acid substitutions within the exposed loop or in the hinge region have less deleterious effects on secretion than changes near the carboxyl end of the protein and, in most cases, do not result in type I HAE. A few mutations of the chain termination type (frameshift or stop codon) have also been described in the 5' portion of exon 8 of type I patients (36) (37) (38) . Another explanation for the biased distribution of mutations within exon 8 could lie at the DNA level. The 3' half of the coding portion of exon 8 may be, for structural reasons, more prone to replication errors than the 5' half (see Fig. 2 ). This hypothesis is strengthened by the fact that the double point mutation described in this study occurred de novo (data not shown). Another double point mutation in the reactive center region has been described in a type II patient, i.e., with high plasma levels of a dysfunctional Cl inh protein, but the time of occurrence of these mutations in the family was not known (35) . In another study a 34-bp deletion and a 20-bp duplication found in the reactive center coding region helped identify a palindromic sequence capable of forming a strong secondary structure (35a). Whether this potential secondary structure in the reactive center coding region predisposes to mutations in the 3' half of the coding portion of exon 8 is unknown. Only one of the mutations described in our study, i.e., the one responsible for R472stop, was at a hypermutable CpG dinucleotide and was found twice in apparently unrelated patients. Moreover, the same mutation has also been found in another study (35a).
The classification of HAE patients into separate groups (type I and type II) according to the quantitative plasma levels (low or high) of Cl inh does not always correlate with distinct categories of molecular defects. For example, mutants V451M and P476S (Fig. 8 ) are secreted at low levels but are dysfunctional and therefore determine a compound phenotype associating the dysfunctional condition of type II with the strongly reduced plasma levels of type I HAE. This dysfunctional fraction can readily be detected (Eldering, E., E. Verpy, D. Roem, T. Meo, and M. Tosi, manuscript submitted for publication) by using the conformation-specific monoclonal antibody KOK 12 (34, and references therein).
The precise mechanisms leading, in HAE patients, to functional C1 inh plasma levels between 5 and 30% of normal instead of the 50% expected from the expression of a single normal allele are still unknown. An increased catabolism of the normal Cl inh protein was found in HAE patients (39) . Recently, studies on patients fibroblasts suggested that certain mutant Cl-INH alleles may trans-inhibit the expression of the normal product at a pretranslational (40) in vivo, depending on the cell type, the level of expression, the structure and the intracellular stability of the mutant protein.
Separate expression of each of the two changes found in the patient with the double point mutation showed that the L459R mutation, which affects a rather conserved residue (see Fig. 9 ), is responsible for the defective transport of the protein while the Q452E mutation, though introducing a charged residue, has no effect on protein expression. Moreover, this mutation does not seem to alter the main properties of the reactive site loop, as the Q452E mutant protein forms apparently normal complexes with Cls (Fig. 8) . From amino acid alignments of the serpins (Fig. 9) Figs. 6 and 7) . The ER appears to play a "quality control" role on the newly synthesized proteins which leads to retention and/or degradation of misfolded, unassembled or aggregated proteins. Although most of the studies on nonlysosomal, pre-Golgi degradation concern membrane proteins (41) (42) (43) (44) (45) (46) , the same quality control mechanism was reported for some soluble luminal proteins. Numerous variants of a1-antitrypsin (al-AT), the prototype of the serpin family, are retained and degraded within the cell (for review see reference 47). It was shown that the PiNullHong Kong and the PiZ mutants are retained and degraded in early compartments (48, 49) . The unassembled immunoglobulin K light chain (50) , secretory immunoglobulin M in B lymphocytes (51) and a frameshift mutant of /3-hexosaminidase (52) were also shown to be degraded in a pre-Golgi compartment. Depending on the protein studied, proteolysis was reported to occur in the ER itself (42, 44) and/ or in a post-ER compartment (46, 49, 51) . Further experiments, at the ultrastructural level, are required to identify the site(s) of degradation of Cl inh mutant proteins. Moreover, it would be interesting to determine whether calnexin, a recently identified molecular chaperone that selectively associates with incompletely folded glycoproteins of the secretory pathway including al-antitrypsin and al-antichymotrypsin (53) , is implicated in the retention and degradation of mutant Cl inh proteins.
The most likely explanation for the intracellular retention or degradation of C1 inh proteins mutated near the carboxyl end is that the mutations prevent the proteins from proper folding. Valine 451 is located, according to the antitrypsin model (54) in the / sheet strand IC. The V451M substitution, although affecting a residue not strictly conserved among serpins (Fig.  9 ) and resembling the neutral polymorphism located 6 residues downstream (indicated below the Cl inh sequence in Fig. 9 ), does affect intracellular transport, even though not dramatically, indicating that valine 451 is important for folding of Cl inh into its native conformation. An alanine to threonine substitution was found at the same position in antithrombin III (ATIII) Paris 3 (55) , in a patient with reduced antigenic plasma levels, suggesting that it was not normally secreted. Amino acid substitutions at other positions of strand IC of ATIII have also been found in patients with reduced antigenic plasma levels (55) . The other Cl inh mutation leading to a partially secreted protein which also accumulates within the cell is the replacement of proline 476 by the polar serine. According to the antitrypsin model, proline 476 is internal, close to the conserved F293 (F208 in a 1-AT coordinates) and initiates the one turn COOHterminal helix (54) of Cl inh. The absolute conservation of this proline in the serpin family (see Fig. 9 ) also suggests that P476 is necessary for the serpins to adopt their native conformation. In vitro mutagenesis experiments have indeed shown that truncation of al-AT immediately before proline 391 (equivalent to P476 of Cl inh) reduces transport from the ER to the Golgi apparatus and that truncation immediately after P391 has no effect on secretion (56) . Thus, it is not surprising that the truncated R472stop Cl inh is rapidly degraded in the ER. The proline equivalent to P476 of Cl inh was also found to be a leucine in ATIII in a patient with severe thromboembolic episodes (57). However, the antigenic plasma levels were normal, suggesting that this particular substitution does not affect intracellular transport of antithrombin III. Phenylalanine 455 (54) . Given the nature of the mutations affecting these residues it is more than likely that folding of the mutant proteins is dramatically affected. Substitution, in strand SB (Fig. 9) , of the conserved glycine residue with arginine has been recently described in a pathogenic ATIII mutant, but the molecular consequences of this change have not been described (58) .
Defects of intracellular transport and secretion represent one of the major groups among the biochemical abnormalities produced by mutations in the Cl INH gene. In addition to the examples described here, deletions of exon 4, observed in several families (19), determine the production of a mutant protein with an internal in phase deletion of 45 amino acids, which is also blocked at early stages of its intracellular transport (59) .
In the case of mutants V451M and P476S, which accumulate intracellularly but are also partially secreted, intracellular folding is probably much closer to wild-type than with the other pathogenic mutants described here. However, lack of recognition of the secreted fraction of V45 IM and P476S Cl inh by the target protease CIs (Fig. 8) 
